| |AUGUST 20268TOP STORIESMERCK STEPS INTO EBOLA VACCINE DEAL TO SCALE PRODUCTIONALL FOUR DENGUE STRAINS FOUND AHEAD OF VACCINE ROLLOUTMILITARY MEDICINE PUSH SETS NEW BENCHMARK IN INDIAN HEALTHCAREASTRAZENECA AND ANDHRA TEAM UP FOR SMARTER CANCER TREATMENTSUGAMMADEX INJECTION ENTRY LIFTS GLENMARK US PORTFOLIOEbola Vaccine gains momentum as Merck partners with a global health group to advance manufacturing to clinical supply by 2026. The collaboration focuses on scaling production capacity and ensuring broader access in outbreak-prone regions.Merck continues to build on its experience in Ebola vaccine development while aligning with global health priorities to strengthen preparedness. The partnership targets faster clinical readiness, improved supply chains, and enhanced distribution frameworks. POIndia has detected dengue strains from all four virus serotypes ahead of the dengue vaccine rollout. The finding comes from a nationwide surveillance study. It has raised attention because infection with different serotypes can increase the risk of severe disease. The results may help shape vaccination plans and strengthen disease monitoring across the country.The study found dengue virus serotypes DENV-1, DENV-2, DENV-3, and DENV-4 circulating across eight states and Union Territories. Experts said this is the first time such nationwide evidence has confirmed the presence of all four serotypes together. The findings arrive as India prepares to introduce its first dengue vaccine. POMilitary medicine now drives a transformative shift in Indian healthcare. India launches its first dedicated academic and operational department for this critical domain. This military medicine initiative integrates clinical care, research, and battlefield preparedness within a structured institutional framework.Indian healthcare gains a strategic upgrade through focused training, trauma response systems, and defense-specific medical innovation. Authorities designed the department to address combat injuries, disaster response, and extreme-environment healthcare challenges. POThe AstraZeneca and Andhra team-up for smarter cancer treatment marks a major step in India's healthcare sector. Andhra Pradesh has signed a Memorandum of Understanding (MoU) with the global pharmaceutical company.The partnership aims to build a precision oncology ecosystem across the state. It will improve cancer care through advanced technologies and personalized treatment. The initiative also focuses on better diagnosis, research, and patient outcomes. The collaboration is expected to make Andhra Pradesh a leader in precision medicine and cancer management. POSugammadex Injection strengthens Glenmark's US portfolio as the company launches its generic version in the United States, targeting hospital segments. Glenmark Pharmaceuticals introduced Sugammadex Injection in multiple strengths, including 200 mg/2 mL and 500 mg/5 mL, addressing surgical anesthesia reversal needs.The launch follows USFDA approval and positions Glenmark in a market valued at nearly USD 1.6 billion annually, based on branded drug sales. Sugammadex Injection supports rapid recovery from neuromuscular blockade during surgeries, making it critical in operating rooms. Glenmark aims to expand its injectable portfolio and capture market share through this strategic US entry. PO
< Page 7 | Page 9 >